Treatment-naїve Mantle Cell Lymphoma

1 clinical trials · Condition

Record	Firm	Date
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma (NCT05051891)	Beijing InnoCare Pharma Tech Co., Ltd.	2021-12-22

Every clearance here is in the API, with alerts when new ones post.